Switch theme
Sign up to access all valuation multiples
BioSig Technologies Inc is a medical device technology company with an advanced digital signal processing technology platform, the PURE EP Platform (PURE EP), that delivers insights to electrophysiologists for ablation treatments of cardiovascular arrhythmias. The PURE EP Platform enables electrophysiologists to acquire raw signal data in real-time, absent unnecessary noise or interference, to maximize procedural success and minimize unnecessary inefficiencies.
2009
8
Last FY Revenue $40K
Last FY EBITDA -$12.4M
$152M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
In the most recent fiscal year, BioSig Technologies achieved revenue of $40K and an EBITDA of -$12.4M.
BioSig Technologies expects next 12-month revenue of XXX and NTM EBITDA of XXX
See BioSig Technologies valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | n/a | XXX | $40K | XXX | XXX | XXX |
| Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA | n/a | XXX | -$12.4M | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -31052% | XXX | XXX | XXX |
| EBIT | -$9.0M | XXX | -$12.6M | XXX | XXX | XXX |
| EBIT Margin | n/a | XXX | -31522% | XXX | XXX | XXX |
| Net Profit | -$7.9M | XXX | -$10.3M | XXX | XXX | XXX |
| Net Margin | n/a | XXX | -25825% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of August 15, 2025, BioSig Technologies's stock price is $5.
BioSig Technologies has current market cap of $156M, and EV of $152M.
See BioSig Technologies trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $152M | $156M | XXX | XXX | XXX | XXX | $-0.44 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of August 15, 2025, BioSig Technologies has market cap of $156M and EV of $152M.
BioSig Technologies's trades at 3803.3x EV/Revenue multiple, and -12.2x EV/EBITDA.
Equity research analysts estimate BioSig Technologies's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
BioSig Technologies has a P/E ratio of -19.6x.
See valuation multiples for BioSig Technologies and 15K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $156M | XXX | $156M | XXX | XXX | XXX |
| EV (current) | $152M | XXX | $152M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | 3803.3x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | -12.2x | XXX | XXX | XXX |
| EV/EBIT | -17.0x | XXX | -12.1x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | -19.6x | XXX | -15.1x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -32.0x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialBioSig Technologies's revenue per employee in the last FY averaged $5K, while opex per employee averaged $1.6M for the same period.
BioSig Technologies's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
BioSig Technologies's rule of X is n/a (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for BioSig Technologies and other 15K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -31052% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $5K | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $1.6M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 2080% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 31622% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Philips | XXX | XXX | XXX | XXX | XXX | XXX |
| Perspective Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| SmartVest | XXX | XXX | XXX | XXX | XXX | XXX |
| InfuSystem | XXX | XXX | XXX | XXX | XXX | XXX |
| Myomo | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
BioSig Technologies acquired XXX companies to date.
Last acquisition by BioSig Technologies was XXXXXXXX, XXXXX XXXXX XXXXXX . BioSig Technologies acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 65K+ M&A deals.
Start Free Trial| When was BioSig Technologies founded? | BioSig Technologies was founded in 2009. |
| Where is BioSig Technologies headquartered? | BioSig Technologies is headquartered in United States of America. |
| How many employees does BioSig Technologies have? | As of today, BioSig Technologies has 8 employees. |
| Who is the CEO of BioSig Technologies? | BioSig Technologies's CEO is Mr. Henry McPhie. |
| Is BioSig Technologies publicy listed? | Yes, BioSig Technologies is a public company listed on NAS. |
| What is the stock symbol of BioSig Technologies? | BioSig Technologies trades under BSGM ticker. |
| When did BioSig Technologies go public? | BioSig Technologies went public in 2014. |
| Who are competitors of BioSig Technologies? | Similar companies to BioSig Technologies include e.g. Philips, Perspective Therapeutics, SmartVest, InfuSystem. |
| What is the current market cap of BioSig Technologies? | BioSig Technologies's current market cap is $156M |
| Is BioSig Technologies profitable? | Yes, BioSig Technologies is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
